ATE120091T1 - Vip-konjugate und deren aktive fragmente mit hydrophoben anteilen und topische zuberetungen zur verwendung in der behandlung männlicher impotenz. - Google Patents

Vip-konjugate und deren aktive fragmente mit hydrophoben anteilen und topische zuberetungen zur verwendung in der behandlung männlicher impotenz.

Info

Publication number
ATE120091T1
ATE120091T1 AT89112463T AT89112463T ATE120091T1 AT E120091 T1 ATE120091 T1 AT E120091T1 AT 89112463 T AT89112463 T AT 89112463T AT 89112463 T AT89112463 T AT 89112463T AT E120091 T1 ATE120091 T1 AT E120091T1
Authority
AT
Austria
Prior art keywords
treatment
vip
hydrophobic
conjugates
motions
Prior art date
Application number
AT89112463T
Other languages
English (en)
Inventor
Illana Gozes
Matityahu Fridkin
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE120091T1 publication Critical patent/ATE120091T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT89112463T 1988-07-08 1989-07-07 Vip-konjugate und deren aktive fragmente mit hydrophoben anteilen und topische zuberetungen zur verwendung in der behandlung männlicher impotenz. ATE120091T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL8705588A IL87055A (en) 1988-07-08 1988-07-08 Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them

Publications (1)

Publication Number Publication Date
ATE120091T1 true ATE120091T1 (de) 1995-04-15

Family

ID=11059032

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89112463T ATE120091T1 (de) 1988-07-08 1989-07-07 Vip-konjugate und deren aktive fragmente mit hydrophoben anteilen und topische zuberetungen zur verwendung in der behandlung männlicher impotenz.

Country Status (7)

Country Link
US (1) US5147855A (de)
EP (1) EP0354992B1 (de)
JP (1) JP2682702B2 (de)
AT (1) ATE120091T1 (de)
DE (1) DE68921814T2 (de)
ES (1) ES2072875T3 (de)
IL (1) IL87055A (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
US5447912A (en) * 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
ZA912984B (en) * 1990-04-25 1992-01-29 Alza Corp Treatment of erectile dysfunction
DE69101187T2 (de) * 1990-06-26 1994-09-29 Sanwa Kagaku Kenkyusho Co VIP-Analogen und ihre Verwendung.
IL99924A (en) * 1991-10-31 1995-12-31 Yeda Res & Dev Derivatives of structurally modified vip and pharmaceutical compositions containing them
US5998368A (en) * 1991-10-31 1999-12-07 Yeda Research And Development Co. Ltd. Derivatives of structurally modified VIP and pharmaceutical compositions containing them
EP0618927A4 (de) * 1991-12-10 1995-05-24 Tanox Biosystems Inc Cytokine mit einem ungepaarten cystein-rest und konjugaten davon.
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
BR9203277A (pt) * 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
US5382392A (en) * 1993-02-05 1995-01-17 Alliedsignal Inc. Process for fabrication of carbon fiber-reinforced carbon composite material
US5972883A (en) * 1993-03-16 1999-10-26 Yeda Research And Development Co. Ltd. Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
WO1994022460A1 (en) * 1993-04-05 1994-10-13 University Patents, Inc. Diagnosis and treatment of erectile dysfunction
US6007836A (en) * 1993-05-28 1999-12-28 Vericade, Inc. Transdermal vasodilator
US5333621A (en) * 1993-05-28 1994-08-02 Eric Denzer Condom with transdermal vasodilator
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
CA2295595A1 (en) 1997-07-09 1999-01-21 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
US6828304B1 (en) 2000-07-31 2004-12-07 Dabur Research Foundation Peptides for treatment of cancer
AU2000265054A1 (en) * 2000-07-31 2002-02-13 Dabur Research Foundation Lipid-peptide conjugates for treatment of cancer
AU2072002A (en) * 2000-11-28 2002-06-11 Mondobiotech Sa Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
WO2007073486A2 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
CN102131516B (zh) 2008-06-27 2016-03-16 杜克大学 包含弹性蛋白样肽的治疗剂
US9029505B2 (en) * 2009-08-14 2015-05-12 Phasebio Pharmaceuticals, Inc. Modified vasoactive intestinal peptides
CA2873553C (en) 2011-06-06 2020-01-28 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
US11052132B2 (en) 2014-05-08 2021-07-06 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
CN114652817B (zh) 2015-02-09 2026-04-17 费斯生物制药公司 用于治疗肌肉疾病和病症的方法和组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3879371A (en) * 1971-09-17 1975-04-22 Sami I Said Isolation of vasoactive intestinal peptide
FR2308266A1 (fr) * 1975-04-18 1976-11-12 Telecommunications Sa Procede de transmission dans des reseaux de connexion temporels a grande capacite
DE3064888D1 (en) * 1979-04-30 1983-10-27 Hoechst Ag Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
US4605641A (en) * 1984-10-09 1986-08-12 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
GB8427651D0 (en) * 1984-11-01 1984-12-05 Beecham Group Plc Compounds
GB8525852D0 (en) * 1985-10-19 1985-11-20 Beecham Group Plc Compounds
JPS62135407A (ja) * 1985-12-10 1987-06-18 Meiji Seika Kaisha Ltd 育毛剤
JPS62246595A (ja) * 1986-04-17 1987-10-27 Eisai Co Ltd 気菅支拡張作用・降圧作用ペプタイド
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4939224A (en) * 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
SE8702520D0 (sv) * 1987-06-16 1987-06-16 Kabigen Ab Mammal intestine hormone precursor
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US4935492A (en) * 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides

Also Published As

Publication number Publication date
ES2072875T3 (es) 1995-08-01
IL87055A0 (en) 1988-12-30
EP0354992A3 (de) 1991-01-16
US5147855A (en) 1992-09-15
EP0354992A2 (de) 1990-02-21
IL87055A (en) 1994-06-24
JP2682702B2 (ja) 1997-11-26
JPH0276821A (ja) 1990-03-16
EP0354992B1 (de) 1995-03-22
DE68921814T2 (de) 1995-09-28
DE68921814D1 (de) 1995-04-27

Similar Documents

Publication Publication Date Title
ATE120091T1 (de) Vip-konjugate und deren aktive fragmente mit hydrophoben anteilen und topische zuberetungen zur verwendung in der behandlung männlicher impotenz.
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
ATE92080T1 (de) Isolierung und strukturbestimmung des zytostatischen linearen depsipeptids dolastatin 15.
EP0206291A3 (en) Sprayable pharmaceutical preparation for topical application
FI952302L (fi) Pyran-2-onit ja 5,6-dihydropyranonit, jotka ovat käyttökelpoisia HIV:n ja muiden retrovirusten hoidossa
PH23222A (en) Immunoglobulin conjugates and pharmaceutical formulation thereof
EP0177342A3 (de) Orale Formulierungen therapeutischer Proteine
ATE60713T1 (de) Pharmazeutische zusammensetzung aus guar-gummi und anderen antiacida zum schutz der oeso-gastro- duodenalen schleimhaut.
ATE135905T1 (de) Bioadhäsive zusammensetzung und pflaster
SE8800080L (sv) Laekemedelskomposition
FI884240A0 (fi) Menetelmä paikalliseen käyttöön tarkoitetun farmaseuttisen valmisteen valmistamiseksi
EP0230264A3 (en) Pharmaceutical composition for nasal application, process for its preparation and its use
DK0773782T3 (da) Terpenderivater (sarcodictyiner) anvendelse som antitumormidler
KR960705578A (ko) 경증 질환을 가진 b형 간염 보균자의 치료방법(method for treating hepatitis b carriers with minimal disease)
WO1989012380A3 (en) Therapeutic uses of 2',5'-oligoadenylate derivatives
IT1206822B (it) Derivati di glicina in qualita' di agenti preventivi e terapeutici del le complicanze diabetiche
DE69131517D1 (de) Verwendung von Prostaglandin-E1 zur Behandlung männlicher erektiler Impotenz
DE69010523D1 (de) Kit oder Zusammensetzung zur Vorbeugung oder Behandlung von HIV-1 Infektionen.
DK68388A (da) Anvendelse af oxochinazolinderivater til fremstilling af laegemidler til behandling af hyperurikaemi
EA199900438A1 (ru) Препарат местного применения для введения пептидных лекарственных средств в живые организмы
KR900017599A (ko) 종양 치료용 약학 조성물
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
ATE157670T1 (de) Digitoxigenin und dihydrodigitoxigenin 3-beta- derivate und pharmazeutische präparate davon, zur behandlung von hypertonie
DE3777411D1 (de) Mittel zur verbesserung der perkutanen verabreichung von arzneimitteln.
DE60217302D1 (de) Erhaltung von körpereigenen proteinen